- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06370000
Oral azacitidin hos transplantationsberättigade patienter med akut myeloid leukemi (AML) som lider av ojämlikhet i hälsa (REMAIN1)
KVAR 1: Återfallsförebyggande med underhåll Oral azacitidin hos transplantationsberättigade patienter med akut myeloid leukemi som inte fortsätter att transplanteras på grund av rasmässiga eller socioekonomiska skillnader
Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a non-randomized open-label single institution pilot study that will evaluate the feasibility, toxicity, and efficacy of maintenance oral azacitidine in medically transplant eligible non-FMS-like tyrosine kinase 3 (FLT3) mutated AML patients with a disadvantage in at least 1 of the 5 key Center for Disease Control and Prevention (CDC) defined social determinants of health (SDOH) domains that are preclusive to transplant at time of study enrollment, as identified either by the patient or a member of the healthcare team.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studiekontakt
- Namn: Massey IIT Research Operations
- Telefonnummer: 804-628-6430
- E-post: masseyepd@vcu.edu
Studieorter
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23298
- Rekrytering
- Virginia Commonwealth University
-
Huvudutredare:
- Keri Maher, DO
-
Kontakt:
- Massey CTO Heme Team
- Telefonnummer: 804-628-6430
- E-post: MasseyHemMlg@vcu.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed non-Acute Promyelocytic (APL) FLT3 negative AML and have completed induction and consolidation as defined by the treating physician and must be in complete response (CR), Complete response with partial hematologic recovery (CRh), or Complete response with incomplete count recovery (CRi) at time of study enrollment
- For patients in CR1, AML disease phenotype must be one that is considered for allo HCT in CR1 (intermediate or high risk by European Leukemia Net (ELN), MRD+ CR, slow clearance of MRD) or any AML phenotype (aside from FLT3+ and APL) in CR2 and beyond
- Medically eligible for allogeneic hematopoietic cell transplant (allo HCT) as defined by either: treating physician discretion, transplant physician discretion, or hematopoietic cell transplantation-specific Comorbidity index (HCT-CI) index of 5 or less
- Age ≥ 18 years
- Enrollment must occur within 4 months of completion of therapy
- A patient or staff identified health disparity in 1 of the 5 Centers for Disease Control (CDC) defined social determinants of health (SDOH). This may include financial difficulties, lack of caregiver support, difficulties with medical literacy, rurality, appropriate access to health care, lack of an appropriate allogeneic hematopoietic cell transplant (allo HCT) donor, substance abuse
- Patient must have adequate organ function defined as: Creatinine clearance (by Cockroft-Gault formula) greater than or equal to 29 mL/min, total bilirubin and aspartate aminotransferase/ alanine transaminase (AST/ALT) ≤ to institutional 2x upper limit of normal (except Gilbert's syndrome, which may enroll if < 2x patient's baseline total bilirubin)
- Eastern Cooperative Oncology Group (ECOG) 0,1,2,3
- Ability to take oral medications
- No history of malabsorption syndrome which, in the investigator's opinion, may inhibit absorption of oral medications
- Women of childbearing potential must consent to effective contraception during study treatment and at least 6 months following the last dose. Women who are breastfeeding are also excluded
- Male patients must consent to effective contraception during study and at least 3 months after last dose
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria A patient who meets any of the following exclusion criteria is ineligible to participate in the study.
- FMS-like tyrosine kinase 3 (FLT3 ITD) or tyrosine kinase domain (TKD) mutation
- Uncontrolled central nervous system (CNS) involvement
- History of hypersensitivity or allergic reaction to azacitidine or its components
- Stem cell transplant within previous 3 months prior to initiation of study therapy
- Uncontrolled intercurrent illness or infection
- History of prior therapy with oral azacitidine
- Female patients who are pregnant or intend to donate eggs during the study or for 6 months after receiving their last dose of study drug
- Male patients who intend to donate sperm during the course of this study or for 3 months after last dose
- Other malignancy for which the patient is currently receiving therapy (except excisable skin cancer)
- Medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk or limit the participant's adherence with study requirements
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Oral Azacitidine
Starting dose is oral azacitidine 300 mg orally once daily with or without food days 1-14 in a 28-day cycle |
Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Tidsram: 4 months
|
The number of participants that complete at least four cycles of protocol therapy |
4 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall survival (OS)
Tidsram: 3 months, and up to 2 years
|
Number of participants alive at relapse, completion of treatment or removal from study. |
3 months, and up to 2 years
|
|
Leukemia Free Survival (LFS) 3 months after beginning of treatment and at relapse, completion of treatment or removal from study
Tidsram: 3 months, and up to 2 years
|
Number of participants still in remission 3 months after beginning of treatment and at relapse, completion of treatment or removal from study |
3 months, and up to 2 years
|
|
Measure rates of measurable residual disease (MRD) negativity
Tidsram: 3 months, and up to 2 years
|
The number of participants that have negative measurable residual disease (MRD) at 3 months after beginning of treatment, and completion of treatment. MRD will be measured by flow cytometry and by pathologic complete response (PCR) based molecular assay if/when target gene is available on diagnostic specimen. |
3 months, and up to 2 years
|
|
Assess whether such an approach may provide an effective bridge to curative intent allogeneic hematopoietic stem cell transplant (alloHCT)
Tidsram: Up to 2 years
|
Number of patients who successfully move on to receive an allogeneic hematopoietic stem cell transplant (alloHCT). |
Up to 2 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Keri Maher, DO, Virginia Commonwealth University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Hematologiska sjukdomar
- Leukemi, myeloid
- Leukemi
- Hemiska och lymfsjukdomar
- Leukemi, Myeloid, Akut
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Nukleinsyror, nukleotider och nukleosider
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- AZA -föreningar
- Nukleosider
- Ribonukleosider
- Azacitidin
Andra studie-ID-nummer
- MCC-23-20817
- HM20029540 (Annan identifierare: Virginia Commonwealth University)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
There is no plan to share individual patient data. Datasets are available on reasonable request to the author.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .